Abstract:Alteration of essential metabolic pathways is a major mechanism by which oncogenic KRAS promotes tumor development and growth in pancreatic ductal adenocarcinoma (PDAC). KRAS-driven PDAC is dependent on nutrient scavenging pathways, including macropinocytosis and autophagy to fuel the high metabolic demand of rapid proliferation. Thus, these metabolic processes are attractive targets for the development of treatments for PDAC. KRAS loss results in downregulation of macropinocytosis in PDAC. Additionally, our lab demonstrated that KRAS loss or inhibition of ERK MAPK signaling decreased glucose consumption and glycolysis but increased autophagy, thereby enhancing dependency on autophagy for survival and growth. Accordingly, dual ERK MAPK and autophagy inhibition (via chloroquine) synergistically enhanced anti-tumor efficacy in PDAC. Early clinical data has demonstrated that resistance to this treatment arises over time through unknown mechanisms. Our preliminary data indicates that following ERK MAPK inhibition both autophagy induction and macropinocytosis downregulation is transient—with autophagic and macropinocytic activity returning to/surpassing basal levels after prolonged treatment. The underlying mechanistic and signaling crosstalk between autophagy and macropinocytosis remains poorly understood. We hypothesize that there is compensatory regulation between autophagy and macropinocytosis signaling following ERK MAPK inhibition. We propose that prolonged activation of autophagy upregulates macropinocytosis over time, consequently abrogating dependency on autophagy and therefore reducing sensitivity to autophagy inhibition. We demonstrate an inverse temporal relationship between autophagic flux and macropinocytosis following genetic loss of KRAS or pharmacological inhibition of the KRAS-ERK MAPK pathway. Furthermore, we show that chloroquine, which is commonly thought of as a lysosomotropic drug, does not prevent degradation of proteins engulfed via macropinocytosis. Together our data suggest that upregulation of macropinocytosis may mediate resistance to the combination of ERK MAPK inhibition and chloroquine. Additionally, we present the unexpected observation that prolonged pharmacological inhibition of the ERK MAPK pathway results in the upregulation of macropinocytosis. Furthermore, we demonstrate that this upregulation of macropinocytosis is accompanied by increased albumin uptake and sensitivity to albumin-bound paclitaxel (nab-paclitaxel). Given the dependence of PDAC on macropinocytic uptake for tumorigenic growth, as well as the potential to exploit macropinocytosis for drug-delivery, it is imperative to understand how ERK MAPK inhibitors regulate macropinocytosis. A better understanding of the regulation underlying these essential metabolic pathways will better inform future ERK MAPK inhibitor combinations. Citation Format: Ryan Robb, Kirsten L. Bryant. Elucidation and exploitation of critical nutrient scavenging regulation in ERK MAPK inhibited pancreatic cancer [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Pancreatic Cancer; 2023 Sep 27-30; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(2 Suppl) nr C077.

The nonreceptor tyrosine kinase SRMS inhibits autophagy and promotes tumor growth by phosphorylating the scaffolding protein FKBP51

RSK2 protects human breast cancer cells under endoplasmic reticulum stress through activating AMPKα2-mediated autophagy

YY1-MIR372-SQSTM1 Regulatory Axis in Autophagy

Phosphorylation of ETS1 by Src Family Kinases Prevents Its Recognition by the COP1 Tumor Suppressor.

SRSF1 inhibits autophagy through regulating Bcl-x splicing and interacting with PIK3C3 in lung cancer

Blocking tumor growth by targeting autophagy and SQSTM1 in vivo

Oncogenic RAS Induces a Distinctive Form of Non-Canonical Autophagy Mediated by the P38-ULK1-PI4KB Axis

Macrophage Syk-PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression

MAP kinase and autophagy pathways cooperate to maintain RAS mutant cancer cell survival

Blockage of Extracellular Signal-Regulated Kinase Exerts an Antitumor Effect via Regulating Energy Metabolism and Enhances the Efficacy of Autophagy Inhibitors by Regulating Transcription Factor EB Nuclear Translocation in Osteosarcoma

Therapeutic strategies targeting AMPK-dependent autophagy in cancer cells

Selective autophagy of AKAP11 activates cAMP/PKA to fuel mitochondrial metabolism and tumor cell growth

The role of SIRT1 in autophagy and drug resistance: unveiling new targets and potential biomarkers in cancer therapy

The MTORC1-mediated autophagy is regulated by the FBXW7-SHOC2-RPTOR axis.

Abstract 1969: Off-target autophagy inhibition by SHP2 allosteric inhibitors and therapeutic implications for aberrant RAS-driven cancers

Autophagy dictates sensitivity to PRMT5 inhibitor in breast cancer

SPHK1 potentiates colorectal cancer progression and metastasis via regulating autophagy mediated by TRAF6-induced ULK1 ubiquitination

SNX14 inhibits autophagy via the PI3K/AKT/mTOR signaling cascade in breast cancer cells

Nintedanib and Dasatinib Treatments Induce Protective Autophagy as a Potential Resistance Mechanism in MPM Cells

Cathepsin K inhibition induces Raptor destabilization and mitochondrial dysfunction via Syk/SHP2/Src/OTUB1 axis-mediated signaling

Abstract C077: Elucidation and exploitation of critical nutrient scavenging regulation in ERK MAPK inhibited pancreatic cancer